93 related articles for article (PubMed ID: 18520057)
1. In vitro and in vivo studies on plasma-to-blood ratio of paclitaxel in human, rabbit and rat blood fractions.
Liu XR; Wu KC; Huang Y; Sun JB; Ke XY; Wang JC; Lu WL; Zhang X; Zhang Q
Biol Pharm Bull; 2008 Jun; 31(6):1215-20. PubMed ID: 18520057
[TBL] [Abstract][Full Text] [Related]
2. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
Sparreboom A; van Zuylen L; Brouwer E; Loos WJ; de Bruijn P; Gelderblom H; Pillay M; Nooter K; Stoter G; Verweij J
Cancer Res; 1999 Apr; 59(7):1454-7. PubMed ID: 10197613
[TBL] [Abstract][Full Text] [Related]
3. Systemic toxicity induced by paclitaxel in vivo is associated with the solvent cremophor EL through oxidative stress-driven mechanisms.
Campos FC; Victorino VJ; Martins-Pinge MC; Cecchini AL; Panis C; Cecchini R
Food Chem Toxicol; 2014 Jun; 68():78-86. PubMed ID: 24657178
[TBL] [Abstract][Full Text] [Related]
4. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
[TBL] [Abstract][Full Text] [Related]
5. Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.
Yokogawa K; Jin M; Furui N; Yamazaki M; Yoshihara H; Nomura M; Furukawa H; Ishizaki J; Fushida S; Miwa K; Miyamoto K
J Pharm Pharmacol; 2004 May; 56(5):629-34. PubMed ID: 15142340
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel.
Loos WJ; Szebeni J; ten Tije AJ; Verweij J; van Zomeren DM; Chung KN; Nooter K; Stoter G; Sparreboom A
Anticancer Drugs; 2002 Aug; 13(7):767-75. PubMed ID: 12187334
[TBL] [Abstract][Full Text] [Related]
7. Distribution of paclitaxel in plasma and cerebrospinal fluid.
Gelderblom H; Baker SD; Zhao M; Verweij J; Sparreboom A
Anticancer Drugs; 2003 Jun; 14(5):365-8. PubMed ID: 12782943
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282
[TBL] [Abstract][Full Text] [Related]
9. Intravenous administration of paclitaxel in Sprague-Dawley rats: what is a safe dose?
Shord SS; Camp JR
Biopharm Drug Dispos; 2006 May; 27(4):191-6. PubMed ID: 16566060
[TBL] [Abstract][Full Text] [Related]
10. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
Gelderblom H; Verweij J; van Zomeren DM; Buijs D; Ouwens L; Nooter K; Stoter G; Sparreboom A
Clin Cancer Res; 2002 Apr; 8(4):1237-41. PubMed ID: 11948138
[TBL] [Abstract][Full Text] [Related]
11. Measurement of fraction unbound paclitaxel in human plasma.
Brouwer E; Verweij J; De Bruijn P; Loos WJ; Pillay M; Buijs D; Sparreboom A
Drug Metab Dispos; 2000 Oct; 28(10):1141-5. PubMed ID: 10997930
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
[TBL] [Abstract][Full Text] [Related]
13. [Comparative study on pharmacokinetics and tissue distribution of a novel microemulsion based on the paclitaxel/L-OH lipid complex and paclitaxel injection in cremophor].
Ma YL; Ye J; Zhang PX; Xia XJ; Liu YL
Yao Xue Xue Bao; 2013 Nov; 48(11):1698-704. PubMed ID: 24475708
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients.
Henningsson A; Sparreboom A; Sandström M; Freijs A; Larsson R; Bergh J; Nygren P; Karlsson MO
Eur J Cancer; 2003 May; 39(8):1105-14. PubMed ID: 12736110
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of paclitaxel-containing liposomes in rats.
Fetterly GJ; Straubinger RM
AAPS PharmSci; 2003 Nov; 5(4):E32. PubMed ID: 15198520
[TBL] [Abstract][Full Text] [Related]
16. The development of a quantitative and qualitative method based on UHPLC-QTOF MS/MS for evaluation paclitaxel-tetrandrine interaction and its application to a pharmacokinetic study.
Li D; Cao Z; Liao X; Yang P; Liu L
Talanta; 2016 Nov; 160():256-267. PubMed ID: 27591612
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.
van Zuylen L; Karlsson MO; Verweij J; Brouwer E; de Bruijn P; Nooter K; Stoter G; Sparreboom A
Cancer Chemother Pharmacol; 2001 Apr; 47(4):309-18. PubMed ID: 11345647
[TBL] [Abstract][Full Text] [Related]
18. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment.
Knemeyer I; Wientjes MG; Au JL
Cancer Chemother Pharmacol; 1999; 44(3):241-8. PubMed ID: 10453726
[TBL] [Abstract][Full Text] [Related]
19. Determination of paclitaxel in rat plasma by LC-MS-MS.
Tong X; Zhou J; Tan Y
J Chromatogr Sci; 2006; 44(5):266-71. PubMed ID: 16774712
[TBL] [Abstract][Full Text] [Related]
20. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo.
Varma MV; Panchagnula R
Eur J Pharm Sci; 2005; 25(4-5):445-53. PubMed ID: 15890503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
